The NCI Clinical Proteomic Technologies for Cancer (CPTC) initiative (see http://proteomics.cancer.gov/) seeks to foster the building of an integrated foundation of proteomic technologies, data, reagents and reference materials, and analysis systems to systematically advance the application of protein science to accelerate discovery and clinical research in cancer. Of the hundreds of cancer biomarkers very few of these candidates have been validated, and even fewer have made it into a medical diagnostic product. This discrepancy indicates that the issue lies within the candidate biomarker pipeline. CPTC has funded the production and uniform characterization of an initial set of monoclonal antibodies to human proteins associated with cancer. Antigens and antibodies were expressed, purified, produced and characterized using standard operating procedures (SOPs). These highly characterized antibodies and associated data are accessible to the public at CPTC Reagents Data Portal (see http://antibodies.cancer.gov/).
The Collaborative Opportunity
The CPTC is looking for a limited number of partners with monoclonal antibodies to cancer related proteins to undergo the same rigorous CPTC characterization regimen. A prospective partner must be willing to make the collected characterization data and the antibodies publically available. Monoclonal antibodies to cancer targets should include different clones of the same antibody, antibodies to different epitopes/regions of the subject protein (i.e. full length vs. truncations, etc.), and/or modifications (i.e. +/- phosphorylations, etc.). Distribution of the characterized antibodies could be through the CPTC Reagents Data Portal or through the collaborator''''''''s channels (academic, nonprofit or commercial). The availability of these highly characterized reagents and the associated data for specific cancer related proteins will add to the core resources available to the NCI Clinical Proteomic Technology Assessment for Cancer Centers and will likely be invaluable tools to the entire research community.
Minimum Criteria for Consideration
A minimum of ten (10) antibodies must be provided;
o React with novel targets not already found in the CPTC antibody catalog;
o React with post-translationally modified targets (e.g. phosphorylated);
o Meets other CPTC programmatic needs.
Prospective partners would at minimum agree to the following:
Interested parties should provide a brief statement of interest and a description of the antibodies to cancer related proteins available (no more than two pages total). NCI will review proposals to determine if they satisfy programmatic needs of the CPTC. NCI reserves the right to enter into an agreement with any partner(s) or none at all. Proposals should be sent to:
Jeffrey W. Thomas, Ph.D.
Technology Transfer Center
1003 West 7th Street
Fairview Center, Suite 500
Frederick, MD 21701
This opportunity is also listed under the following categories: